Davide Melisi Selected Research

Oxaliplatin (Eloxatin)

1/2020	A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial.
10/2009	Oral poly(ADP-ribose) polymerase-1 inhibitor BSI-401 has antitumor activity and synergizes with oxaliplatin against pancreatic cancer, preventing acute neurotoxicity.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Davide Melisi Research Topics

Disease

50	Neoplasms (Cancer) 04/2024 - 04/2003
31	Pancreatic Neoplasms (Pancreatic Cancer) 01/2024 - 04/2008
15	Adenocarcinoma 01/2024 - 03/2015
10	Stomach Neoplasms (Stomach Cancer) 04/2024 - 12/2016
7	Neoplasm Metastasis (Metastasis) 04/2024 - 04/2008
5	Carcinogenesis 02/2018 - 05/2009
4	Inflammation (Inflammations) 09/2023 - 02/2018
4	Cholangiocarcinoma 02/2021 - 01/2020
4	Breast Neoplasms (Breast Cancer) 05/2017 - 04/2003
3	Biliary Tract Neoplasms (Biliary Tract Cancer) 05/2024 - 10/2022
2	Hepatocellular Carcinoma (Hepatoma) 01/2023 - 01/2021
2	Disease Progression 01/2020 - 10/2019
2	Colorectal Neoplasms (Colorectal Cancer) 08/2017 - 10/2011
2	Male Breast Neoplasms (Male Breast Cancer) 05/2017 - 03/2016
2	Lung Neoplasms (Lung Cancer) 01/2015 - 08/2004
2	Colonic Neoplasms (Colon Cancer) 01/2004 - 04/2003
1	Fibrosis (Cirrhosis) 09/2023
1	Shock 01/2023
1	Respiratory Insufficiency (Respiratory Failure) 01/2023
1	Neutropenia 01/2023
1	Multiple Organ Failure (MODS) 01/2023
1	Diarrhea 01/2023
1	Hypertension (High Blood Pressure) 01/2023
1	Melanoma (Melanoma, Malignant) 01/2022
1	Acinar Cell Carcinoma 01/2022
1	Squamous Cell Neoplasms (Squamous Cell Cancer) 12/2021
1	Glioma (Gliomas) 12/2021

Drug/Important Bio-Agent (IBA)

20	Gemcitabine FDA Link 05/2024 - 04/2008
11	Biomarkers (Surrogate Marker)IBA 04/2024 - 09/2011
9	Phosphotransferases (Kinase)IBA 01/2021 - 08/2005
8	ErbB Receptors (EGF Receptor)IBA 05/2014 - 04/2003
7	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 08/2017 - 04/2003
6	pemigatinibIBA 03/2023 - 01/2020
6	Proteins (Proteins, Gene)FDA Link 11/2019 - 08/2005
5	Irinotecan (Camptosar)FDA LinkGeneric 01/2024 - 01/2019
5	130-nm albumin-bound paclitaxelIBA 10/2023 - 04/2015
5	LY-2157299IBA 09/2023 - 11/2018
5	Tyrosine Kinase InhibitorsIBA 01/2023 - 04/2003
5	Transcription Factors (Transcription Factor)IBA 11/2020 - 02/2007
4	Cisplatin (Platino)FDA LinkGeneric 05/2024 - 10/2020
4	Leucovorin (Folinic Acid)FDA Link 01/2023 - 05/2017
4	Fluorouracil (Carac)FDA LinkGeneric 01/2023 - 05/2017
4	Gefitinib (Iressa)FDA Link 12/2005 - 04/2003
3	Trastuzumab (Herceptin)FDA Link 03/2023 - 12/2016
3	Mitogen-Activated Protein KinasesIBA 01/2022 - 10/2011
3	Transforming Growth Factor beta (TGF-beta)IBA 01/2021 - 04/2008
3	Small Interfering RNA (siRNA)IBA 01/2020 - 05/2009
3	Bevacizumab (Avastin)FDA Link 08/2017 - 09/2011
3	Monoclonal AntibodiesIBA 01/2016 - 08/2004
3	OligonucleotidesIBA 08/2014 - 04/2003
3	LuciferasesIBA 08/2011 - 04/2008
3	vandetanib (ZD6474)IBA 08/2008 - 01/2004
2	EnzymesIBA 09/2023 - 12/2005
2	Immune Checkpoint InhibitorsIBA 01/2023 - 12/2021
2	Sorafenib (BAY 43-9006)FDA Link 01/2023 - 01/2021
2	durvalumabIBA 01/2021 - 11/2018
2	Angiogenesis InhibitorsIBA 11/2020 - 01/2013
2	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2020 - 10/2009
2	Interleukin-8 (Interleukin 8)IBA 01/2020 - 08/2017
2	Hormones (Hormone)IBA 10/2018 - 03/2016
2	Angiopoietin-like ProteinsIBA 02/2018 - 08/2017
2	LigandsIBA 08/2017 - 01/2016
2	Everolimus FDA Link 05/2017 - 03/2016
2	CytokinesIBA 01/2017 - 05/2009
2	Interleukin-1 Receptors (Interleukin 1 Receptor)IBA 03/2016 - 01/2016
2	Interleukin 1 Receptor Antagonist Protein (Anakinra)FDA Link 03/2016 - 01/2016
2	Toll-Like Receptor 9IBA 08/2014 - 10/2011
2	Cetuximab (Erbitux)FDA Link 10/2011 - 01/2004
2	DNA (Deoxyribonucleic Acid)IBA 10/2009 - 04/2003
2	NF-kappa B (NF-kB)IBA 05/2009 - 02/2007
2	Vascular Endothelial Growth Factor Receptor-1 (fms-Like Tyrosine Kinase)IBA 08/2008 - 08/2005
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 02/2006 - 08/2004
2	4- (5- (4- chlorophenyl)- 3- (trifluoromethyl)- 1H- pyrazol- 1- yl)benzenesulfonamideIBA 12/2005 - 04/2003
2	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 12/2005 - 04/2003
2	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 08/2005 - 01/2004
1	lysophosphatidic acidIBA 09/2023
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2023
1	camrelizumabIBA 01/2023
1	Alanine Transaminase (SGPT)IBA 01/2023
1	apatinibIBA 01/2023
1	Proto-Oncogene Proteins B-rafIBA 01/2022
1	alectinibIBA 01/2022
1	p38 Mitogen-Activated Protein KinasesIBA 01/2022
1	SOXB1 Transcription FactorsIBA 01/2022
1	futibatinibIBA 01/2022
1	LY3300054IBA 12/2021
1	Antineoplastic Agents (Antineoplastics)IBA 12/2021
1	B7-H1 AntigenIBA 01/2021
1	3- (9- fluoro- 2- (piperidin- 1- ylcarbonyl)- 1,2,3,4- tetrahydro(1,4)diazepino(6,7,1- hi)indol- 7- yl)- 4- imidazo(1,2- a)pyridin- 3- yl- 1H- pyrrole- 2,5- dioneIBA 01/2020

Therapy/Procedure

39	Therapeutics 11/2023 - 01/2004
25	Drug Therapy (Chemotherapy) 05/2024 - 08/2005
3	Neoadjuvant Therapy 04/2024 - 01/2018
3	Radiotherapy 01/2013 - 08/2004
2	Immunotherapy 01/2023 - 12/2018
2	Nutritional Support (Artificial Feeding) 01/2020 - 01/2018
2	Aftercare (After-Treatment) 08/2018 - 04/2003
2	Oral Administration 08/2011 - 04/2003
1	Treatment Delay 11/2023
1	Drug Tapering 01/2023
1	Continuity of Patient Care 01/2023